Ignite Creation Date:
2024-05-06 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 2:27 PM
Study NCT ID:
NCT05286437
Status:
RECRUITING
Last Update Posted:
2024-03-05
First Post:
2022-03-09
Brief Title:
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Sponsor:
National Cancer Centre Singapore
Organization:
National Cancer Centre Singapore
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-15
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-09
First Submit QC Date:
March 9 2022
Study First Post Date:
2022-03-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-04
Last Update Post Date:
2024-03-05
Last Update Post Date Type:
ACTUAL